Chemotherapy-associated lineage shift of T/myeloid mixed-phenotype acute leukemia into AML-MRC: a case report
- 5 November 2025
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (3) , 704-708
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapyAnnals of Hematology, 2025
- Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patientsLeukemia, 2024
- Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk groupThe Lancet Haematology, 2023
- Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context ofTP53alterations and venetoclax treatmentLeukemia & Lymphoma, 2022
- Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case seriesLeukemia & Lymphoma, 2021
- Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemiaAnnals of Hematology, 2021
- Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute LeukemiaCase Reports in Hematology, 2021
- Acute lymphoblastic leukemia–like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patientsAnnals of Hematology, 2020
- Transformation of myelodysplastic syndrome to mixed phenotype acute leukaemiaeJHaem, 2020
- The genetic basis and cell of origin of mixed phenotype acute leukaemiaNature, 2018